

Appl. No. : National Phase Entry of PCT/KR2003/002552
Applicant : Jin Wan KIM, *et al.*
Filed : Herewith
TC/A.U. : Not Yet Assigned
Examiner : Not Yet Assigned

Docket No. : 1751-381
Customer No. : 06449
Confirmation No. : Not Yet Assigned

SUBMISSION OF SUBSTITUTE SPECIFICATION

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

A substitute specification is being submitted herewith. A clean copy and marked copy of the specification are attached. No new matter has been added.

Respectfully submitted,

By: G. F. Rothwell
G. Franklin Rothwell
Registration No. 18,125
Attorney for Applicant
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

METHOD FOR PREPARING OLTIPRAZ

CROSS REFERENCE TO RELATED APPLICATION


This application is a 35 U.S.C. § 371 National Phase Entry Application from PCT/KR03/002552, filed November 25, 2003, and designating the U.S.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

[Para 1] The present invention relates to a method for preparing oltipraz represented by Formula 1 below:

Formula 1




DESCRIPTION OF THE RELATED ART

[Para 2] Oltipraz represented by Formula 1 above was originally developed as an anti-schistosomal drug that eliminates parasites known blood flukes by Rhone-Poulenc, in 1980. However, during clinical trials, it was found that oltipraz does not have excellent drug effect relative to praziquantel that had been currently used for the treatment of parasite infections, and thus oltipraz was later abandoned.

[Para 3] Thereafter, in studies on a new reaction mechanism of oltipraz conducted in the 1990s, it was reported that oltipraz is effective for the inhibition of HIV propagation [Prochaska et al., 1995], the prevention and treatment of cancers, and the inhibition of HBV transcription [Chi et al., 1998].

[Para 4] Methods for preparing oltipraz are disclosed in U.S. Patent No. 4,110,450, assigned to Rhone-Poulenc, issued in 1978. This patent provides two methods for preparing oltipraz, one of which is as following Scheme 2.


Scheme 2



[Para 5] According to Scheme 2, however, the duration for preparation of oltipraz is too long, as 18 to 24 hours. Also, after a Claisen condensation reaction between ethyl pyrazine-2-carboxylate and ethyl propionate, separation and purification using a column are done. Furthermore, a total yield achieved after two steps of Scheme 2 above is 4.2%, which is too low for mass production.

[Para 6] Another method for preparing oltipraz disclosed in the above patent is as following Scheme 3.


Scheme 3



[Para 7] The method of Scheme 3 includes an additional reaction step, as compared to the method of Scheme 2. Like in Scheme 2, a total yield is too low for mass production.

[Para 8] WO01/09118, issued on August 2001, discloses a method for preparing oltipraz as following Scheme 4:

Scheme 4



[Para 9] In the above method, since sodium hydride is used as a base in a Claisen condensation reaction, there is an explosion risk of hydrogen produced during the condensation reaction. Also, since sodium hydride dispersed in oil is used, a pretreatment for oil removal is required. In particular, excess phosphorus

pentasulfide (P_2S_5) inevitably used in the formation of a dithiolethione ring may cause severe environmental contamination. In addition, like in the above-described methods, a lengthy reaction duration is required.

[Para 10] Steps influencing the total yield of oltipraz in oltipraz preparation methods are a Claisen condensation reaction step in the presence of strong base and a dithiolethione ring formation step using P_2S_5 .

[Para 11] In formation of dithiolethione rings from 3-oxoester compounds, a method of enhancing the yield of dithiolethione using various reagents such as P_2S_5 , Lawesson's reagent, sulfur (S)/ P_2S_5 , or hexamethyldisiloxane/ P_2S_5 has been reported [Tetrahedron Letters 2000, p.9965, 17-18]. However, the yield of 3-oxoester compounds with a nitrogen-containing hetero ring is very low, and in particular, the yield of oltipraz with a pyrazinyl group is extremely low, as less than 10%.

SUMMARY OF THE INVENTION


[Para 12] Therefore, while searching for solutions to the above problems, the present inventors developed a novel method for preparing oltipraz in which a 3-oxoester compound can be produced in high yield in the presence of a strong base with no explosion risk, and the duration for formation of a dithiolethione ring is significantly reduced, and completed the present invention.

[Para 13] The present invention provides a method for preparing oltipraz.


DETAILED DESCRIPTION OF THE INVENTION

[Para 14] The present invention provides a method for preparing oltipraz represented by Formula 1, including reacting methyl 2-methyl-3-(pyrazin-2-yl)-3-oxopropionate represented by Formula 4 with phosphorus pentasulfide (P_2S_5) in the presence of a mixed solvent of toluene and xylene, followed by recrystallization.

Formula 1



Formula 4



Preferably, the volume ratio of toluene to xylene in the mixed solvent is in a range of 1:1 to 1:4.


[Para 15] Since the mixed solvent of toluene and xylene has a high boiling point, a reflux temperature can be efficiently increased. The activity of P_2S_5 increases with increasing reaction temperature. This is supported by the results of experiments using toluene, xylene, tetrahydrofuran, or methylenechloride, that as a reaction temperature increases, the activity of P_2S_5 increases. In this regard, the use of the mixed solvent of toluene and xylene can increase a reaction yield.

[Para 16] Also, due to the use of the mixed solvent, the reaction duration for formation of dithiolethione is reduced to 4 to 6 hours, which is time effective. This is in contrary to a conventional method requiring 18 to 24 hours for the formation of dithiolethione.

[Para 17] Preferably, P_2S_5 is used in an amount of 0.5 to 3 equivalents, more preferably, 1.05 to 1.50 equivalents, based on 1 equivalent of methyl 2-methyl-3-(pyrazin-2-yl)-3-oxopropionate.

[Para 18] The methyl 2-methyl-3-(pyrazin-2-yl)-3-oxopropionate of Formula 4 may be produced by a Claisen condensation reaction between methyl pyrazine-2-carboxylate represented by Formula 3 below and methyl propionate in the presence of a strong base.

Formula 3



[Para 19] The strong base may be sodium hydroxide, potassium hydroxide, sodium t-butoxide, potassium t-butoxide, or sodium amide. Potassium t-butoxide is preferred.


[Para 20] A solvent that can be used in the condensation reaction is a nonreactive solvent commonly used in an organic reaction, i.e., toluene, methylenechloride, or tetrahydrofuran. Tetrahydrofuran is preferred.

[Para 21] A conventional method includes a separation and/or purification step after the Claisen condensation reaction, or another additional reaction step, which creates commercial inefficiency. However, under the above-described optimal reaction condition, a high purity product can be obtained even when a separation and/or purification process is not used. Also, a single solvent can be reused after distilled, thereby contributing to cost curtailment effect.

[Para 22] Preferably, the strong base is used in an amount of 1.5 to 2.5 equivalents, more preferably, 1.8 to 2.0 equivalents, based on 1 equivalent of methyl pyrazine-2-carboxylate.

[Para 23] The methyl pyrazine-2-carboxylate of Formula 3 may be produced by an esterification reaction of pyrazine-2-carboxylic acid represented by Formula 2 below in a methanol solution in the presence of an acid catalyst such as sulfuric acid under reflux.

Formula 2




[Para 24] In the esterification reaction, it was found that the amount of an acid catalyst is closely related to a reaction duration. Through studies on increase or decrease of the amount of an impurity, which is a byproduct, with increasing the amount of an acid catalyst, the present inventors found that an increase of the amount of an acid catalyst enables to a reduction of a reaction duration without producing an impurity, which increases a production efficiency relative to the prior art.

[Para 25] The acid catalyst that can be used in the esterification reaction is an inorganic acid commonly commercially available, for example, sulfuric acid, hydrochloric acid, or phosphoric acid. The most preferable acid catalyst is sulfuric acid. Due to an increase of the amount of the acid catalyst, pyrazine-2-carboxylate can be obtained without an increase of an impurity by reflux of 4 to 5 hours, which is in contrary to a conventional reflux time of 48 hours. Preferably, the amount of the acid catalyst is in a range of 5.8×10^{-3} to 25.0×10^{-3} equivalents, based on 1 mole of methyl pyrazine-2-carboxylic acid.

[Para 26] The overall reaction of the above-described method for preparing oltipraz can be summarized as follows.

Scheme 1



[Para 27] After all the reactions are completed, an oltipraz crude crystal is obtained as a final product. A crystallization solvent for the oltipraz crude crystal may be methanol, ethanol, ethylacetate, or acetonitrile. The most preferable crystallization solvent is methanol.

[Para 28] The oltipraz crude crystal may be purified using a recrystallization solvent selected from the group consisting of acetonitrile, methanol, N,N-dimethylformamide, N,N-dimethylacetamide, and a mixed solvent thereof.

[Para 29] When the recrystallization solvent is acetonitrile, it is preferable to use 30 to 40 parts by volume of acetonitrile, based on 1 part by weight of the oltipraz crude crystal.

[Para 30] When the recrystallization solvent is a mixed solvent of N,N-dimethylformamide and acetonitrile, it is preferable to use 15 to 20 parts by volume of N,N-dimethylformamide and 30 and 40 parts by volume of acetonitrile, based on 1 part by weight of the oltipraz crude crystal.

[Para 31] When the recrystallization solvent is a mixed solvent of N,N-dimethylformamide and methanol, it is preferable to use 15 to 20 parts by volume of N,N-dimethylformamide and 30 to 40 parts by volume of methanol, based on 1 part by weight of the oltipraz crude crystal.

[Para 32] If the amount of the recrystallization solvent is outside the above range, the yield of a product significantly reduces. Also, the recrystallization solvent may be remained in the product.

[Para 33] Hereinafter, the present invention will be described more specifically by examples. However, the following examples are provided only for illustrations and thus the present invention is not limited to or by them.

Example 1**Methyl pyrazine-2-carboxylate (Formula 3)**

[Para 34] 20.0 g (805.8 mmole) of pyrazine-2-carboxylic acid was added to 160 mL of methanol, and 1.0 mL of a concentrated sulfuric acid was gradually dropwise added thereto with stirring. A reaction solution was refluxed at a temperature of 80 to 85°C for 5 hours. The reaction solution was cooled to a temperature of 20 to 22°C and concentrated to a volume of 25mL. Then, 80 mL of methylenechloride and 40 mL of water were added to the resultant concentrate. The resultant solution was then neutralized by gradual addition of 40 mL of a saturated sodium hydrogen carbonate solution to get a pH of 8.5. An organic layer was separated and a water layer was extracted again with 40 mL of methylenechloride. The combined organic layer was dried over anhydrous magnesium sulfate, filtered, and washed with 20 mL of methylenechloride. A filtrate was concentrated to give 21.1 g of the titled compound as a pale brown solid (yield 94.8%).

Melting point: 60 ~ 61°C

Example 2**Methyl 2-methyl-3-(pyrazin-2-yl)-3-oxopropionate (Formula 4)**

[Para 35] 1.2 L of tetrahydrofuran and 87.8 g (0.78 mole) of potassium t-butoxide were added to a reactor and cooled to 0°C. 71.5 mL (0.74 mol) of methyl propionate was dropwise added to the reactor and stirred at 0°C for 30 minutes. 60 g (0.434 mole) of the methyl pyrazine-2-carboxylate of Example 1 dissolved in 500 mL of tetrahydrofuran was dropwise added to the reactor for 30 minutes and stirred at a temperature of 20 to 25°C for 3 hours. 0.5 L of distilled water and 0.5 L of saturated ammonium chloride solution were added to the reaction solution and stirred for 30 minutes. The resultant reaction solution was concentrated to a volume of 1.0 L and then extracted with 1.0 L of methylenechloride. The resultant

extract was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated to give 75.0 g of the titled compound as a dark brown viscous oil (yield 89.0%).

NMR(δ , CDCl_3): 1.50(d, 3H), 3.65(s, 3H), 4.70(q, 1H), 8.60(d, 1H), 8.80(d, 1H), 9.21(s, 1H)

Example 3

Synthesis and recrystallization of oltipraz

[Para 36] 300 mL of toluene, 350 mL of xylene, and 48.0 g (216 mmole) of phosphorus pentasulfide were added to a reactor and heated to a temperature of 120 to 122°C. 40.0 g (206 mmole) of methyl 2-methyl-3-(pyrazin-2-yl)-3-oxopropionate prepared in Example 2 was dissolved in 100 mL of toluene and then dropwise added to the reactor. The reaction solution was allowed to proceed under reflux at 135°C for 4 hours and then cooled to 20°C. After addition of 500 mL of distilled water and 500 mL of methanol, the pH of the resultant reaction solution was adjusted to 8.5 with adding a 28% ammonia solution (about 51 mL). An organic layer was separated, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 150 mL of methanol was added to the resultant concentrate, stirred for one hour, and filtered. A filtrate was washed with 100 mL of methanol to give a humid oltipraz crude crystal (12.0 to 13.0 g).

[Para 37] The oltipraz crude crystal was placed in a reactor. 400 mL of acetonitrile was added and dissolved at 80°C. 1.4 g of activated carbon was added and stirred for 30 minutes. The resultant solution was filtered, washed with 100 mL of acetonitrile, crystallized with stirring at a temperature of 20 to 25°C for 2 hours, and again stirred at 10°C for one hour. The obtained crystal was filtered, washed with 20 mL of acetonitrile, and vacuum dried at 40°C to give 6.37 g of

oltipraz (13.6% yield, >99.5% purity).

NMR(δ , CDCl_3): 2.51(s, 3H), 8.70(d, 1H), 8.80(d, 1H), 9.21(s, 1H)

Example 4

Recrystallization of oltipraz

[Para 38] An oltipraz crude crystal prepared in the same manner in Example 3 and 180 mL of N,N-dimethylformamide were placed in a reactor and dissolved at 80°C. Then, 1.4 g of activated carbon was added and stirred for 30 minutes. The resultant solution was filtered and washed with 20 mL of N,N-dimethylformamide. 360 mL of acetonitrile was dropwise added at 80°C, crystallized with stirring at 20 to 25°C for 2 hours, and again stirred at 10°C for one hour. The resultant crystal was filtered, washed with 20 mL of acetonitrile, and vacuum dried at 40°C to give 7.15 g of oltipraz (15.6% yield, >99.6% purity).

NMR(δ , CDCl_3): 2.51(s, 3H), 8.70(d, 1H), 8.80(d, 1H), 9.21(s, 1H)

Example 5

Recrystallization of oltipraz

[Para 39] An oltipraz crude crystal prepared in the same manner in Example 3 and 180 mL of N,N-dimethylformamide were placed in a reactor and dissolved at 80°C. Then, 1.4 g of activated carbon was added and stirred for 30 minutes. The resultant solution was filtered and washed with 20 mL of N,N-dimethylformamide. 360 mL of methanol was dropwise added at 80°C, crystallized with stirring at 20 to 25°C for 2 hours, and again stirred at 10°C for one hour. The resultant crystal was filtered, washed with 20 mL of methanol, and vacuum dried at 40°C to give 7.53 g of

oltipraz (16.1% yield, >99.6% purity).

NMR(δ , CDCl_3): 2.51(s, 3H), 8.70(d, 1H), 8.80(d, 1H), 9.21(s, 1H).

[Para 40] According to an oltipraz preparation method of the present invention, there exists no explosion risk of hydrogen produced and a reaction duration is reduced. In addition, impurity separation and purification processes in the interim reaction process are not required, thereby ensuring the economical mass production of oltipraz.